ReviewNature reviews. Drug discovery2024
Navigating the complexities of drug development for inflammatory bowel disease.
Review in Nature reviews. Drug discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative clinical efficacy of acupuncture-related therapies for ulcerative colitis: a systematic review and network meta-analysis.Frontiers in medicine · 2025Pooled it
- Safety, Pharmacokinetics, Food effect, and Pharmacodynamics of AJM347, a Selective α4β7 Integrin Antagonist: A First-in-Human Single- and Multiple-Ascending Dose Study in Healthy Male Volunteers.Journal of clinical pharmacology · 2026Trial
- Intestinal epithelial Syndecan-1 maintains mucosal homeostasis in inflammatory bowel disease by enhancingGut microbes · 2026Article
- Triptolide loaded cerium oxide nanozyme based oral nanoplatform for targeted colitis therapy.International journal of pharmaceutics: X · 2026Article
- Targeting Interleukin-7 Signalling in Ulcerative Colitis: Rationale and Emerging Clinical Evidence.Life (Basel, Switzerland) · 2026Review
- Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy.Alimentary pharmacology & therapeutics · 2026Review
- Guselkumab in Inflammatory Bowel Disease: Mechanism, Clinical Efficacy, Safety, and Treatment Positioning.Journal of clinical medicine · 2026Review
- TIPE2 gene knockdown in mice attenuates experimental colitis by diminishing inflammatory cell infiltration.Molecular therapy. Nucleic acids · 2026Article
- ACY-1215 ameliorates experimental colitis by inhibiting dendritic cell maturation and Th1/Th17 responses.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Review
- A gas-liquid biphasic nanocleaner for breaking the self-amplified vicious cycle of barrier disruption-inflammation in inflammatory bowel disease.Journal of nanobiotechnology · 2026Article
- Exome sequencing directly implicates 68 genes in inflammatory bowel disease.medRxiv : the preprint server for health sciences · 2026Article
- Advances in Biosimilars: A Systematic Review of Machine Learning Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Integrating Human Intestinal Organoids into FDA's New Approach Methodologies for Drug Discovery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Artificial intelligence and digital transformation of gastroenterology and hepatology: A critical review of clinical applications and future challenges.World journal of hepatology · 2026Review
- Sodium Butyrate Alleviates IBD by Modulating SIRT1-Involved Ferroptosis and Inhibition of Macrophage Ferroptosis.Nutrients · 2026Article
- Machine learning models for drug-drug interaction prediction from computational discovery to clinical application.NPJ digital medicine · 2026Review
- IBDkb: an AI-enhanced integrative knowledge base for inflammatory bowel disease research and drug discovery.Database : the journal of biological databases and curation · 2026Article
- A decade of clinical data with vedolizumab: the past, present, and future.Therapeutic advances in gastroenterology · 2026Review
- Mental Health Disorders in Pediatric Inflammatory Bowel Disease: Epidemiology, Mechanisms, and Interventions.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) - consisting of ulcerative colitis and Crohn's disease - is a complex, heterogeneous, immune-mediated inflammatory condition with a multifactorial aetiopathogenesis. Despite therapeutic advances in this arena, a ceiling effect has been reached with both single-agent monoclonal antibodies and advanced small molecules. Therefore, there is a need to identify novel targets, and the development of companion biomarkers to select responders is vital. In this Perspective, we examine how advances in machine learning and tissue engineering could be used at the preclinical stage where attrition rates are high. For novel agents reaching clinical trials, we explore factors decelerating progression, particularly the decline in IBD trial recruitment, and assess how innovative approaches such as reconfiguring trial designs, harmonizing end points and incorporating digital technologies into clinical trials can address this. Harnessing opportunities at each stage of the drug development process may allow for incremental gains towards more effective therapies.
Indexed as
Identifiers
38778181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.